Ascentage Pharma Group International (AAPG)

Market Cap	1.75B
Revenue (ttm)	124.27M
Net Income (ttm)	-49.58M
Shares Out	309.38M
EPS (ttm)	-0.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	166,219
Open	20.80
Previous Close	19.67
Day's Range	20.50 - 21.40
52-Week Range	16.50 - 21.40
Beta	1.00
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About AAPG

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 24, 2025
• Employees: 583
• Stock Exchange: NASDAQ
• Ticker Symbol: AAPG
• Website: https://www.ascentage.cn

Financial Performance

In 2023, AAPG's revenue was 221.98 million, an increase of 5.85% compared to the previous year's 209.71 million. Losses were -925.64 million, 4.84% more than in 2022.

Financial numbers in CNY